MediciNova Shares Fall After Mixed Phase 2 Results for Fatty Liver Drug MN-001
MediciNova fell after mixed Phase 2 data for MN-001. HDL rose, but week-24 liver fat and triglycerides missed significance in 40 patients.
/ 6 items
#MDGL↓
Wolfe Research Upgrades Madrigal to Outperform: Sees “Rare Opportunity” After Overdone Sell-Off
Wolfe Research views F4 data timing concerns as overblown after Madrigal’s Q2 beat and strong growth performance.
Novo Nordisk Acquires Akero Therapeutics for $5.2 Billion, Securing Key MASH Treatment EFX
Novo Nordisk has agreed to acquire clinical-stage Akero Therapeutics for up to $5.2 billion to integrate efruxifermin (EFX), a promising late-stage treatment for MASH, complementing Novo Nordisk's leadership in cardiometabolic disease.
Pharma Giant Roche Buys 89bio for up to $3.5 Billion to Fight Fatty Liver Disease
Pharma giant Roche bought 89bio for up to $3.5B. The focus is pegozafermin, a promising drug for treating MASH (severe fatty liver disease). This deal positions Roche to transform care in metabolic diseases. Shares of 89bio surged 85% on Thursday.
FDA Breakthrough: New Non-Invasive Biomarker to Revolutionize MASH Drug Development
The FDA accepted non-invasive Liver Stiffness Measurement as a surrogate endpoint for MASH clinical trials, replacing biopsies. This key decision accelerates MASH drug development by enabling safer monitoring, speeding recruitment, and predicting patient outcomes.
Novo's Wegovy Secures Accelerated FDA Approval for MASH
Novo Nordisk's Wegovy (semaglutide) is now FDA-approved for metabolic dysfunction-associated steatohepatitis (MASH) with liver scarring, a significant advancement for this serious condition.